Evidence map›Paper›PMID 23499890›Full record

ReviewCancer letters2013

Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition.

Jeffrey T Chang, Sendurai A Mani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Cytokines, breast cancer stem cells (BCSCs) and chemoresistance.Clinical and translational medicine · 2018
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2014
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jeffrey T ChangDepartment of Integrative Biology and Pharmacology, Medical School, University of Texas Health Science Center, Houston, TX 77030, United States; School of Biomedical Informatics, University of Texas Health Science Center, Houston, TX 77030, United States; Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX 77030, United States. Electronic address: jeffrey.t.chang@uth.tmc.edu.
Sendurai A Mani

Funding

Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progressionR01CA155243 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MANI, SENDURAI AYYAVOO · 2011 to 2022
$3.2M
Functional Components of the Rb/E2F and p53 PathwaysR00LM009837 · NLM · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHANG, JEFFREY T · 2010 to 2012
$699k
NCI NIH HHS R01 CA155243NLM NIH HHS R00 LM009837NLM NIH HHS R00LM009837
6 · The paper itself

Abstract

Multiple cancers contain subpopulations that exhibit characteristics of cancer stem cells (CSCs), the ability to self-renew and seed heterogeneous tumors. Recent evidence suggests two potentially overlapping models for these phenotypes: one where stem cells arise from multipotent progenitor cells, and another where they are created via an epithelial to mesenchymal transition. Unraveling this issue is critical, as it underlies phenomena such as metastasis and therapeutic resistance. Therefore, there is intense interest in understanding these two types of CSSs, how they differ from differentiated cancer cells, the mechanisms that drive their phenotypes, and how that knowledge can be incorporated into therapeutics.

Indexed as

Epithelial-Mesenchymal TransitionAnimalsHumansNeoplasmsNeoplastic Stem CellsCancer stem cellsCellular plasticityEMTEpithelial–mesenchymal transition

Identifiers

PMID23499890
PMCPMC3762892

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.